These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

181 related articles for article (PubMed ID: 26558226)

  • 1. Ranibizumab alone or in combination with photodynamic therapy vs photodynamic therapy for polypoidal choroidal vasculopathy: a systematic review and Meta-analysis.
    Tang K; Si JK; Guo DD; Cui Y; Du YX; Pan XM; Bi HS
    Int J Ophthalmol; 2015; 8(5):1056-66. PubMed ID: 26558226
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Photodynamic therapy in combination with ranibizumab versus ranibizumab monotherapy for polypoidal choroidal vasculopathy: A systematic review and meta-analysis.
    Liu L; Tham YC; Wu J; Yue S; Cheng CY
    Photodiagnosis Photodyn Ther; 2017 Dec; 20():215-220. PubMed ID: 28935532
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Three-year visual outcomes of intravitreal ranibizumab with or without photodynamic therapy for polypoidal choroidal vasculopathy.
    Sakai T; Okano K; Kohno H; Tsuneoka H
    Acta Ophthalmol; 2016 Dec; 94(8):e765-e771. PubMed ID: 27237048
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparison of the effects of photodynamic therapy, intravitreal ranibizumab and combination for polypoidal choroidal vasculopathy under 1 + PRN regimen.
    Lai K; Li Y; Zhou L; Zhong X; Huang C; Xu F; Lu L; Ge J; Jin C
    BMC Ophthalmol; 2018 Jun; 18(1):144. PubMed ID: 29925341
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Efficacy evaluation of photodynamic therapy and intravitreal anti-VEGF injection for polypoidal choroidal vasculopathy: systematic review].
    Wang J; Wang EQ; Chen YX; Tian R
    Zhonghua Yan Ke Za Zhi; 2013 Dec; 49(12):1094-103. PubMed ID: 24499696
    [TBL] [Abstract][Full Text] [Related]  

  • 6. INITIAL VERSUS DELAYED PHOTODYNAMIC THERAPY IN COMBINATION WITH RANIBIZUMAB FOR TREATMENT OF POLYPOIDAL CHOROIDAL VASCULOPATHY: The Fujisan Study.
    Gomi F; Oshima Y; Mori R; Kano M; Saito M; Yamashita A; Iwata E; Maruko R;
    Retina; 2015 Aug; 35(8):1569-76. PubMed ID: 25830698
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy and Safety of Ranibizumab With or Without Verteporfin Photodynamic Therapy for Polypoidal Choroidal Vasculopathy: A Randomized Clinical Trial.
    Koh A; Lai TYY; Takahashi K; Wong TY; Chen LJ; Ruamviboonsuk P; Tan CS; Feller C; Margaron P; Lim TH; Lee WK;
    JAMA Ophthalmol; 2017 Nov; 135(11):1206-1213. PubMed ID: 28983556
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Practicability confirmation by meta-analysis of intravitreal ranibizumab compared to photodynamic therapy to treat polypoidal choroidal vasculopathy.
    Liu L; Ma J; Duan P; Liu Y; Yin ZQ
    Mol Vis; 2015; 21():1130-41. PubMed ID: 26539025
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Combined photodynamic therapy and ranibizumab for polypoidal choroidal vasculopathy: a 2-year result and systematic review.
    Zhao M; Zhou HY; Xu J; Zhang F; Wei WB; Liu NP
    Int J Ophthalmol; 2017; 10(3):413-422. PubMed ID: 28393033
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Intravitreal ranibizumab with or without photodynamic therapy for the treatment of symptomatic polypoidal choroidal vasculopathy.
    Lai TY; Lee GK; Luk FO; Lam DS
    Retina; 2011 Sep; 31(8):1581-8. PubMed ID: 21610566
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Intravitreal ranibizumab injection combined with photodynamic therapy for polypoidal choroidal vasculopathy.
    Li J; Sun J; Li B; Liu Z
    Exp Ther Med; 2018 Feb; 15(2):1546-1551. PubMed ID: 29434739
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparison of one-year results of photodynamic therapy combined with ranibizumab or aflibercept for treating polypoidal choroidal vasculopathy.
    Ito A; Maruyama-Inoue M; Kitajima Y; Sato S; Inoue T; Yamane S; Kadonosono K
    PLoS One; 2020; 15(6):e0235213. PubMed ID: 32579608
    [TBL] [Abstract][Full Text] [Related]  

  • 13. EVEREST study: efficacy and safety of verteporfin photodynamic therapy in combination with ranibizumab or alone versus ranibizumab monotherapy in patients with symptomatic macular polypoidal choroidal vasculopathy.
    Koh A; Lee WK; Chen LJ; Chen SJ; Hashad Y; Kim H; Lai TY; Pilz S; Ruamviboonsuk P; Tokaji E; Weisberger A; Lim TH
    Retina; 2012 Sep; 32(8):1453-64. PubMed ID: 22426346
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Combination of ranibizumab with photodynamic therapy vs ranibizumab monotherapy in the treatment of age-related macular degeneration: a systematic review and meta-analysis of randomized controlled trials.
    Si JK; Tang K; Bi HS; Guo DD; Guo JG; Du YX; Cui Y; Pan XM; Wen Y; Wang XR
    Int J Ophthalmol; 2014; 7(3):541-9. PubMed ID: 24967206
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Complete regression of branching vascular network in polypoidal choroidal vasculopathy by ranibizumab and photodynamic therapy, two case reports.
    Iesato Y; Tanaka M; Murata M; Kitahara J; Hirano T; Kurenuma T; Yoshida N; Murata T
    BMC Ophthalmol; 2018 Nov; 18(1):284. PubMed ID: 30390650
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Two-year results of photodynamic therapy with or without intravitreal ranibizumab for polypoidal choroidal vasculopathy.
    Sakurada Y; Iijima H
    J Ocul Pharmacol Ther; 2013 Nov; 29(9):832-6. PubMed ID: 23962035
    [TBL] [Abstract][Full Text] [Related]  

  • 17. One-year results of intravitreal ranibizumab combined with reduced-fluence photodynamic therapy for polypoidal choroidal vasculopathy.
    Sakurai M; Baba T; Kitahashi M; Yokouchi H; Kubota-Taniai M; Bikbova G; Oshitari T; Yamamoto S
    Clin Ophthalmol; 2014; 8():235-41. PubMed ID: 24511222
    [TBL] [Abstract][Full Text] [Related]  

  • 18. 1-year results of combined half-dose photodynamic therapy and ranibizumab for polypoidal choroidal vasculopathy.
    Wong IY; Shi X; Gangwani R; Zhao P; Iu LP; Li Q; Ng A; Li X
    BMC Ophthalmol; 2015 Jun; 15():66. PubMed ID: 26122636
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Photodynamic therapy in combination with ranibizumab versus ranibizumab monotherapy for wet age-related macular degeneration: A systematic review and meta-analysis.
    Su Y; Wu J; Gu Y
    Photodiagnosis Photodyn Ther; 2018 Jun; 22():263-273. PubMed ID: 29753123
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Two-year follow-up of ranibizumab combined with photodynamic therapy for polypoidal choroidal vasculopathy.
    Nemoto R; Miura M; Iwasaki T; Goto H
    Clin Ophthalmol; 2012; 6():1633-8. PubMed ID: 23109800
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.